This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.

Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.


1klu

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Line 1: Line 1:
-
[[Image:1klu.gif|left|200px]]
+
{{Seed}}
 +
[[Image:1klu.png|left|200px]]
<!--
<!--
Line 9: Line 10:
{{STRUCTURE_1klu| PDB=1klu | SCENE= }}
{{STRUCTURE_1klu| PDB=1klu | SCENE= }}
-
'''Crystal structure of HLA-DR1/TPI(23-37) complexed with staphylococcal enterotoxin C3 variant 3B2 (SEC3-3B2)'''
+
===Crystal structure of HLA-DR1/TPI(23-37) complexed with staphylococcal enterotoxin C3 variant 3B2 (SEC3-3B2)===
-
==Overview==
+
<!--
-
While most immunotherapies for cancer have focused on eliciting specific CD8+ cytotoxic T lymphocyte killing of tumor cells, a mounting body of evidence suggests that stimulation of anti-tumor CD4+ T cell help may be required for highly effective therapy. Several MHC class II-restricted tumor antigens that specifically activate such CD4+ helper T lymphocytes have now been identified, including one from a melanoma tumor that is caused by a single base-pair mutation in the glycolytic enzyme triosephosphate isomerase. This mutation results in the conversion of a threonine residue to isoleucine within the antigenic epitope, concomitant with a greater than five log-fold increase in stimulation of a CD4+ tumor-infiltrating lymphocyte line. Here, we present the crystal structures of HLA-DR1 in complex with both wild-type and mutant TPI peptide antigens, the first structures of tumor peptide antigen/MHC class II complexes recognized by CD4+ T cells to be reported. These structures show that very minor changes in the binding surface for T cell receptor correspond to the dramatic differences in T cell stimulation. Defining the structural basis by which CD4+ T cell help is invoked in an anti-tumor immune response will likely aid the design of more effective cancer immunotherapies.
+
The line below this paragraph, {{ABSTRACT_PUBMED_12051920}}, adds the Publication Abstract to the page
 +
(as it appears on PubMed at http://www.pubmed.gov), where 12051920 is the PubMed ID number.
 +
-->
 +
{{ABSTRACT_PUBMED_12051920}}
==About this Structure==
==About this Structure==
Line 33: Line 37:
[[Category: Hla-dr1/tpi]]
[[Category: Hla-dr1/tpi]]
[[Category: Human melanoma antigen]]
[[Category: Human melanoma antigen]]
-
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Fri May 2 22:53:47 2008''
+
 
 +
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Wed Jul 2 10:31:43 2008''

Revision as of 07:31, 2 July 2008

Image:1klu.png

Template:STRUCTURE 1klu

Crystal structure of HLA-DR1/TPI(23-37) complexed with staphylococcal enterotoxin C3 variant 3B2 (SEC3-3B2)

Template:ABSTRACT PUBMED 12051920

About this Structure

1KLU is a Protein complex structure of sequences from Homo sapiens and Staphylococcus aureus. Full crystallographic information is available from OCA.

Reference

Minor structural changes in a mutated human melanoma antigen correspond to dramatically enhanced stimulation of a CD4+ tumor-infiltrating lymphocyte line., Sundberg EJ, Sawicki MW, Southwood S, Andersen PS, Sette A, Mariuzza RA, J Mol Biol. 2002 May 31;319(2):449-61. PMID:12051920

Page seeded by OCA on Wed Jul 2 10:31:43 2008

Proteopedia Page Contributors and Editors (what is this?)

OCA

Retrieved from "http://52.214.119.220/wiki/index.php/1klu"
Personal tools